Close
  Indian J Med Microbiol
 

Figure 5: Vincamine attenuated amyloid-β 25-35 induced neurotoxicity in PC12 cells. (A) Apoptosis analysis of PC12 cells treated with amyloid-β 25-35, vincamine, or a combination of them. (a) Untreated cells; (b) 30 μM amyloid-β 25-35-treated cells; (c) 30 μM amyloid-β 25-35 + 20 μM vincamine-treated cells; (d) 30 μM amyloid-β 25-35 + 40 μM vincamine-treated cells; (e) 30 μM amyloid-β 25-35 + 80 μM vincamine-treated cells. Cells were exposed for 48 h. Double staining was used to distinguish between viable (lower left quadrant, annexin V-negative, propidium iodide-negative), early apoptosis (lower right quadrant, annexin V-positive, propidium iodide-negative), late apoptosis and necrotic (upper right quadrant, annexin V-positive, propidium iodide-positive) and cell debris (upper left quadrant). Statistical analysis is shown in (B). *P < 0.05, **P < 0.01, amyloid-β 25-35, vincamine or both treated cells compared with untreated control cells. #P < 0.05, ##P < 0.01, vincamine-treated cells compared with 30 μM amyloid-β 25-35-treated cells. Results are mean ± standard deviation (n = 3)

Figure 5: Vincamine attenuated amyloid-β 25-35 induced neurotoxicity in PC12 cells. (A) Apoptosis analysis of PC12 cells treated with amyloid-β 25-35, vincamine, or a combination of them. (a) Untreated cells; (b) 30 μM amyloid-β 25-35-treated cells; (c) 30 μM amyloid-β 25-35 + 20 μM vincamine-treated cells; (d) 30 μM amyloid-β 25-35 + 40 μM vincamine-treated cells; (e) 30 μM amyloid-β 25-35 + 80 μM vincamine-treated cells. Cells were exposed for 48 h. Double staining was used to distinguish between viable (lower left quadrant, annexin V-negative, propidium iodide-negative), early apoptosis (lower right quadrant, annexin V-positive, propidium iodide-negative), late apoptosis and necrotic (upper right quadrant, annexin V-positive, propidium iodide-positive) and cell debris (upper left quadrant). Statistical analysis is shown in (B). *<i>P <</i> 0.05, **<i>P <</i> 0.01, amyloid-β 25-35, vincamine or both treated cells compared with untreated control cells. #<i>P</i> < 0.05, ##<i>P <</i> 0.01, vincamine-treated cells compared with 30 μM amyloid-β 25-35-treated cells. Results are mean ± standard deviation (<i>n</i> = 3)